Strahlentherapie und Onkologie最新文献

筛选
英文 中文
[Olaparib for high-risk biochemically recurrent prostate cancer following prostatectomy]. [奥拉帕尼用于前列腺切除术后高危生化复发前列腺癌]。
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-03-01 Epub Date: 2024-12-17 DOI: 10.1007/s00066-024-02350-3
Katharina Hintelmann, Lukas Böckelmann
{"title":"[Olaparib for high-risk biochemically recurrent prostate cancer following prostatectomy].","authors":"Katharina Hintelmann, Lukas Böckelmann","doi":"10.1007/s00066-024-02350-3","DOIUrl":"10.1007/s00066-024-02350-3","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"343-345"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MR-linac: role of artificial intelligence and automation.
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-03-01 Epub Date: 2025-01-22 DOI: 10.1007/s00066-024-02358-9
Serena Psoroulas, Alina Paunoiu, Stefanie Corradini, Juliane Hörner-Rieber, Stephanie Tanadini-Lang
{"title":"MR-linac: role of artificial intelligence and automation.","authors":"Serena Psoroulas, Alina Paunoiu, Stefanie Corradini, Juliane Hörner-Rieber, Stephanie Tanadini-Lang","doi":"10.1007/s00066-024-02358-9","DOIUrl":"10.1007/s00066-024-02358-9","url":null,"abstract":"<p><p>The integration of artificial intelligence (AI) into radiotherapy has advanced significantly during the past 5 years, especially in terms of automating key processes like organ at risk delineation and treatment planning. These innovations have enhanced consistency, accuracy, and efficiency in clinical practice. Magnetic resonance (MR)-guided linear accelerators (MR-linacs) have greatly improved treatment accuracy and real-time plan adaptation, particularly for tumors near radiosensitive organs. Despite these improvements, MR-guided radiotherapy (MRgRT) remains labor intensive and time consuming, highlighting the need for AI to streamline workflows and support rapid decision-making. Synthetic CTs from MR images and automated contouring and treatment planning will reduce manual processes, thus optimizing treatment times and expanding access to MR-linac technology. AI-driven quality assurance will ensure patient safety by predicting machine errors and validating treatment delivery. Advances in intrafractional motion management will increase the accuracy of treatment, and the integration of imaging biomarkers for outcome prediction and early toxicity assessment will enable more precise and effective treatment strategies.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"298-305"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Can stereotactic radiotherapy for neovascular age-related macular degeneration (STAR trial) enhance quality of life?] 立体定向放疗治疗新生血管性年龄相关性黄斑变性(STAR试验)能否提高生活质量?]
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-03-01 Epub Date: 2025-01-11 DOI: 10.1007/s00066-024-02351-2
Stephanie Göller, Heinz Schmidberger
{"title":"[Can stereotactic radiotherapy for neovascular age-related macular degeneration (STAR trial) enhance quality of life?]","authors":"Stephanie Göller, Heinz Schmidberger","doi":"10.1007/s00066-024-02351-2","DOIUrl":"10.1007/s00066-024-02351-2","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"346-348"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient- and clinician-based evaluation of large language models for patient education in prostate cancer radiotherapy. 基于患者和临床的前列腺癌放疗患者教育大语言模型评估。
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-03-01 Epub Date: 2025-01-10 DOI: 10.1007/s00066-024-02342-3
Christian Trapp, Nina Schmidt-Hegemann, Michael Keilholz, Sarah Frederike Brose, Sebastian N Marschner, Stephan Schönecker, Sebastian H Maier, Diana-Coralia Dehelean, Maya Rottler, Dinah Konnerth, Claus Belka, Stefanie Corradini, Paul Rogowski
{"title":"Patient- and clinician-based evaluation of large language models for patient education in prostate cancer radiotherapy.","authors":"Christian Trapp, Nina Schmidt-Hegemann, Michael Keilholz, Sarah Frederike Brose, Sebastian N Marschner, Stephan Schönecker, Sebastian H Maier, Diana-Coralia Dehelean, Maya Rottler, Dinah Konnerth, Claus Belka, Stefanie Corradini, Paul Rogowski","doi":"10.1007/s00066-024-02342-3","DOIUrl":"10.1007/s00066-024-02342-3","url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate the capabilities and limitations of large language models (LLMs) for providing patient education for men undergoing radiotherapy for localized prostate cancer, incorporating assessments from both clinicians and patients.</p><p><strong>Methods: </strong>Six questions about definitive radiotherapy for prostate cancer were designed based on common patient inquiries. These questions were presented to different LLMs [ChatGPT‑4, ChatGPT-4o (both OpenAI Inc., San Francisco, CA, USA), Gemini (Google LLC, Mountain View, CA, USA), Copilot (Microsoft Corp., Redmond, WA, USA), and Claude (Anthropic PBC, San Francisco, CA, USA)] via the respective web interfaces. Responses were evaluated for readability using the Flesch Reading Ease Index. Five radiation oncologists assessed the responses for relevance, correctness, and completeness using a five-point Likert scale. Additionally, 35 prostate cancer patients evaluated the responses from ChatGPT‑4 for comprehensibility, accuracy, relevance, trustworthiness, and overall informativeness.</p><p><strong>Results: </strong>The Flesch Reading Ease Index indicated that the responses from all LLMs were relatively difficult to understand. All LLMs provided answers that clinicians found to be generally relevant and correct. The answers from ChatGPT‑4, ChatGPT-4o, and Claude AI were also found to be complete. However, we found significant differences between the performance of different LLMs regarding relevance and completeness. Some answers lacked detail or contained inaccuracies. Patients perceived the information as easy to understand and relevant, with most expressing confidence in the information and a willingness to use ChatGPT‑4 for future medical questions. ChatGPT-4's responses helped patients feel better informed, despite the initially standardized information provided.</p><p><strong>Conclusion: </strong>Overall, LLMs show promise as a tool for patient education in prostate cancer radiotherapy. While improvements are needed in terms of accuracy and readability, positive feedback from clinicians and patients suggests that LLMs can enhance patient understanding and engagement. Further research is essential to fully realize the potential of artificial intelligence in patient education.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"333-342"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep learning for autosegmentation for radiotherapy treatment planning: State-of-the-art and novel perspectives. 用于放疗治疗计划自动分割的深度学习:最新技术和新视角。
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-03-01 Epub Date: 2024-08-06 DOI: 10.1007/s00066-024-02262-2
Ayhan Can Erdur, Daniel Rusche, Daniel Scholz, Johannes Kiechle, Stefan Fischer, Óscar Llorián-Salvador, Josef A Buchner, Mai Q Nguyen, Lucas Etzel, Jonas Weidner, Marie-Christin Metz, Benedikt Wiestler, Julia Schnabel, Daniel Rueckert, Stephanie E Combs, Jan C Peeken
{"title":"Deep learning for autosegmentation for radiotherapy treatment planning: State-of-the-art and novel perspectives.","authors":"Ayhan Can Erdur, Daniel Rusche, Daniel Scholz, Johannes Kiechle, Stefan Fischer, Óscar Llorián-Salvador, Josef A Buchner, Mai Q Nguyen, Lucas Etzel, Jonas Weidner, Marie-Christin Metz, Benedikt Wiestler, Julia Schnabel, Daniel Rueckert, Stephanie E Combs, Jan C Peeken","doi":"10.1007/s00066-024-02262-2","DOIUrl":"10.1007/s00066-024-02262-2","url":null,"abstract":"<p><p>The rapid development of artificial intelligence (AI) has gained importance, with many tools already entering our daily lives. The medical field of radiation oncology is also subject to this development, with AI entering all steps of the patient journey. In this review article, we summarize contemporary AI techniques and explore the clinical applications of AI-based automated segmentation models in radiotherapy planning, focusing on delineation of organs at risk (OARs), the gross tumor volume (GTV), and the clinical target volume (CTV). Emphasizing the need for precise and individualized plans, we review various commercial and freeware segmentation tools and also state-of-the-art approaches. Through our own findings and based on the literature, we demonstrate improved efficiency and consistency as well as time savings in different clinical scenarios. Despite challenges in clinical implementation such as domain shifts, the potential benefits for personalized treatment planning are substantial. The integration of mathematical tumor growth models and AI-based tumor detection further enhances the possibilities for refining target volumes. As advancements continue, the prospect of one-stop-shop segmentation and radiotherapy planning represents an exciting frontier in radiotherapy, potentially enabling fast treatment with enhanced precision and individualization.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"236-254"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141894361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Segment Anything foundation model achieves favorable brain tumor auto-segmentation accuracy in MRI to support radiotherapy treatment planning. Segment Anything 基础模型在核磁共振成像中实现了良好的脑肿瘤自动分割精度,为放疗治疗规划提供了支持。
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-03-01 Epub Date: 2024-11-06 DOI: 10.1007/s00066-024-02313-8
Florian Putz, Sogand Beirami, Manuel Alexander Schmidt, Matthias Stefan May, Johanna Grigo, Thomas Weissmann, Philipp Schubert, Daniel Höfler, Ahmed Gomaa, Ben Tkhayat Hassen, Sebastian Lettmaier, Benjamin Frey, Udo S Gaipl, Luitpold V Distel, Sabine Semrau, Christoph Bert, Rainer Fietkau, Yixing Huang
{"title":"The Segment Anything foundation model achieves favorable brain tumor auto-segmentation accuracy in MRI to support radiotherapy treatment planning.","authors":"Florian Putz, Sogand Beirami, Manuel Alexander Schmidt, Matthias Stefan May, Johanna Grigo, Thomas Weissmann, Philipp Schubert, Daniel Höfler, Ahmed Gomaa, Ben Tkhayat Hassen, Sebastian Lettmaier, Benjamin Frey, Udo S Gaipl, Luitpold V Distel, Sabine Semrau, Christoph Bert, Rainer Fietkau, Yixing Huang","doi":"10.1007/s00066-024-02313-8","DOIUrl":"10.1007/s00066-024-02313-8","url":null,"abstract":"<p><strong>Background: </strong>Promptable foundation auto-segmentation models like Segment Anything (SA, Meta AI, New York, USA) represent a novel class of universal deep learning auto-segmentation models that could be employed for interactive tumor auto-contouring in RT treatment planning.</p><p><strong>Methods: </strong>Segment Anything was evaluated in an interactive point-to-mask auto-segmentation task for glioma brain tumor auto-contouring in 16,744 transverse slices from 369 MRI datasets (BraTS 2020 dataset). Up to nine interactive point prompts were automatically placed per slice. Tumor boundaries were auto-segmented on contrast-enhanced T1w sequences. Out of the three auto-contours predicted by SA, accuracy was evaluated for the contour with the highest calculated IoU (Intersection over Union, \"oracle mask,\" simulating interactive model use with selection of the best tumor contour) and for the tumor contour with the highest model confidence (\"suggested mask\").</p><p><strong>Results: </strong>Mean best IoU (mbIoU) using the best predicted tumor contour (oracle mask) in full MRI slices was 0.762 (IQR 0.713-0.917). The best 2D mask was achieved after a mean of 6.6 interactive point prompts (IQR 5-9). Segmentation accuracy was significantly better for high- compared to low-grade glioma cases (mbIoU 0.789 vs. 0.668). Accuracy was worse using the suggested mask (0.572). Stacking best tumor segmentations from transverse MRI slices, mean 3D Dice score for tumor auto-contouring was 0.872, which was improved to 0.919 by combining axial, sagittal, and coronal contours.</p><p><strong>Conclusion: </strong>The Segment Anything foundation segmentation model can achieve high accuracy for glioma brain tumor segmentation in MRI datasets. The results suggest that foundation segmentation models could facilitate RT treatment planning when properly integrated in a clinical application.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"255-265"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing treatment for Gleason 10 prostate cancer: radiation dose escalation and 68Ga-PSMA-PET/CT staging.
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-02-28 DOI: 10.1007/s00066-025-02376-1
Cem Onal, Ozan Cem Guler, Birhan Demirhan, Petek Erpolat, Aysenur Elmali, Melek Yavuz
{"title":"Optimizing treatment for Gleason 10 prostate cancer: radiation dose escalation and <sup>68</sup>Ga-PSMA-PET/CT staging.","authors":"Cem Onal, Ozan Cem Guler, Birhan Demirhan, Petek Erpolat, Aysenur Elmali, Melek Yavuz","doi":"10.1007/s00066-025-02376-1","DOIUrl":"https://doi.org/10.1007/s00066-025-02376-1","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the effects of dose escalation through focal boost (FB) to intraprostatic lesions (IPLs) as well as the role of gallium-68 prostate-specific membrane antigen positron-emission tomography (<sup>68</sup>Ga-PSMA-PET/CT) for staging and treatment planning in patients with Gleason score (GS) 10 prostate cancer (PCa) receiving definitive radiotherapy (RT) and androgen deprivation therapy (ADT).</p><p><strong>Materials and methods: </strong>We retrospectively analyzed data of 92 patients with GS 10 PCa who underwent definitive RT and ADT from March 2010 to October 2022. Freedom from biochemical failure (FFBF), prostate cancer-specific survival (PCSS), distant metastasis-free survival (DMFS), and overall survival (OS) rates were calculated using the Kaplan-Meier method. Survival outcomes were compared between patients staged with <sup>68</sup>Ga-PSMA-PET/CT and those staged with conventional imaging modalities as well as between those who received a simultaneous integrated boost (SIB) and those who did not.</p><p><strong>Results: </strong>At a median follow-up time of 73 months, the 5‑year FFBF, PCSS, DMFS, and OS rates were 59.2%, 77.0%, 62.9%, and 67.6%, respectively. Disease progression was observed in 39 patients (42.4%), with most cases manifesting as distant metastasis (DM). A total of 56 patients (60.9%) were staged using <sup>68</sup>Ga-PSMA-PET/CT, while 43 patients (46.7%) received FB to IPLs. Patients staged with <sup>68</sup>Ga-PSMA-PET/CT had better FFBF and PCSS compared to those staged with conventional imaging. Patients undergoing an SIB had improved PCSS and DMFS. In the multivariable analysis, an ADT duration of 18 months or more was associated with improved FFBF, PCSS, DMFS, and OS. Application of an SIB was an additional independent predictor for improved FFBF, while staging with <sup>68</sup>Ga-PSMA-PET/CT was associated with better PCSS.</p><p><strong>Conclusion: </strong>We found that long-term ADT, increasing the radiation dose to primary tumor, and staging with <sup>68</sup>Ga-PSMA-PET/CT improved clinical outcomes. Additional research is needed for validation.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Stereotactic ablative radiotherapy (SABR) without chemotherapy in oligometastasized head and neck carcinoma (GORTEC 2014-04 "OMET")]. [少转移头颈部癌无需化疗的立体定向消融放疗(SABR)(GORTEC 2014-04 "OMET")]。
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-02-27 DOI: 10.1007/s00066-025-02384-1
Jörg Andreas Müller, Dirk Vordermark
{"title":"[Stereotactic ablative radiotherapy (SABR) without chemotherapy in oligometastasized head and neck carcinoma (GORTEC 2014-04 \"OMET\")].","authors":"Jörg Andreas Müller, Dirk Vordermark","doi":"10.1007/s00066-025-02384-1","DOIUrl":"https://doi.org/10.1007/s00066-025-02384-1","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advantages of 3D printed patient-individual moulds in brachytherapy for facial skin cancer.
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-02-26 DOI: 10.1007/s00066-025-02372-5
Jörg Licher, Julia Achenbach, Janett Köhn, Markus Diefenhardt, Maximilian Fleischmann, Claus Rödel, Nikolaos Tselis, Ulla Ramm, Christian Scherf
{"title":"Advantages of 3D printed patient-individual moulds in brachytherapy for facial skin cancer.","authors":"Jörg Licher, Julia Achenbach, Janett Köhn, Markus Diefenhardt, Maximilian Fleischmann, Claus Rödel, Nikolaos Tselis, Ulla Ramm, Christian Scherf","doi":"10.1007/s00066-025-02372-5","DOIUrl":"https://doi.org/10.1007/s00066-025-02372-5","url":null,"abstract":"<p><strong>Purpose: </strong>Facial skin cancer of 42 elderly frail patients was treated with individualised 3D-printed mould applicators for high-dose-rate (HDR) brachytherapy. The dosimetric outcome was compared to conventionally manufactured individual moulds used before.</p><p><strong>Methods: </strong>Tumour-adapted HDR brachytherapy source paths were pre-planned and dosimetrically optimised in the brachytherapy treatment planning system (TPS) using computed tomography (CT) data and considered in the design of the patient-individual moulds. Dosimetric outcome for the planning target volumes and organs at risk were statistically evaluated and compared for pre-planning, final clinical treatment planning with TG-43 formalism and retrospective tissue, material and CT density related TG-186 calculations.</p><p><strong>Results: </strong>Pre-planning allows reliable brachytherapy source paths design to achieve intended dosimetric clinical goals. The 3D-printed patient-specific moulds show a clear advantage in the dosimetric coverage of the target volume (improving D<sub>90</sub> from 98.3% to 104.3%) and the protection of the relevant organs at risk (reduction up to 30% of maximum Dose). With the 3D-printed moulds only minor deviations were observed for TG-43 and TG-186 dose recalculations of the treated plans.</p><p><strong>Conclusion: </strong>Customised 3D printed moulds offer a safe and efficient technique to treat facial skin cancer in critical locations and complex clinical situations with HDR brachytherapy. The two-step planning process results in reliable PTV dose coverage and efficient sparing of eye lenses and eyeballs. Dosimetric outcome and interfractional position reproducibility with 3D printed moulds were superior to conventionally manufactured facial moulds with respect to the clinical goals.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143504294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and toxicity of stereotactic radiotherapy combined with third-generation EGFR-TKIs and immunotherapy in patients with brain metastases from non-small cell lung cancer.
IF 2.7 3区 医学
Strahlentherapie und Onkologie Pub Date : 2025-02-26 DOI: 10.1007/s00066-024-02360-1
Xiaoxuan Tao, Qichang Gao, Yiyang Chen, Nannan Cai, Chuncheng Hao
{"title":"Efficacy and toxicity of stereotactic radiotherapy combined with third-generation EGFR-TKIs and immunotherapy in patients with brain metastases from non-small cell lung cancer.","authors":"Xiaoxuan Tao, Qichang Gao, Yiyang Chen, Nannan Cai, Chuncheng Hao","doi":"10.1007/s00066-024-02360-1","DOIUrl":"https://doi.org/10.1007/s00066-024-02360-1","url":null,"abstract":"<p><strong>Objective: </strong>Stereotactic radiotherapy (SRT) is fast gaining attention as a preferred treatment alternative for patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). In this study, we examined the efficacy and safety of combining SRT with immunotherapy (IT) and targeted therapy (TT), either separately or concurrently with the aim to formulate an optimal therapeutic regimen for patients with NSCLC BM.</p><p><strong>Methods: </strong>The combination therapy were comprised of IT and TT agents. For the SRT-combined TT agents group, TT was limited to third-generation EGFR-TKIs. The administration of these drugs within 30 days before or after SRT was defined as combination therapy. The primary endpoint was 1-year progression-free survival (PFS), which was evaluated by a blinded independent review committee and categorized into local recurrence at the radiation site and the emergence of new distant intracranial metastases. Secondary endpoints included confirmed intracranial objective response rate (IORR) and intracranial disease control rate in the overall population. Post-treatment grading was performed according to CTCAE, and the levels of radiation necrosis were differentiated.</p><p><strong>Results: </strong>The 266 patients with NSCLC BM were categorized into the following four groups based on their treatment methods: SRT alone, SRT combined with IT, SRT combined with third-generation EGFR-TKIs, and SRT combined with both IT and TT. For the local radiation range, the 1‑year PFS of these four groups were 77.89% (P = 0.239), 88.75% (P = 0.266), 88.01% (P = 0.210), and 91.97% (P = 0.057), respectively. For new intracranial metastases outside of the radiotherapy site, the corresponding values were 63.96% (P = 0.039), 74.17% (P = 0.258), 88.70% (P = 0.024), and 87.81% (P = 0.015), respectively. By the end of the study period, the IORR increased from 32% with SRT alone to 46% in the IT group, 58% in the TT group, and 61% in the SRT combined with both the IT and TT groups. However, the group that received SRT in combination with IT and TT exhibited a higher occurrence rate of grade 3 adverse events, and a statistically significant difference was observed in grade 3 radiation necrosis.</p><p><strong>Conclusion: </strong>For NSCLC BM, IT, TT, or both together with SRT increased the distant intracranial tumor control. Nonetheless, combining SRT with both IT and TT increased the occurrence rate of acute adverse events. Thus, while SRT provided good local control independently, the incidence of symptomatic RN was low.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143504239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信